Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
UroGen Pharma Ltd. (NASDAQ: URGN)
URGN Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
55.90%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
43.20%
URGN Stock Analysis
URGN
PE Ratio:
URGN
PEG Ratio:
Not Available
URGN
Forward EPS Growth (12 month):
0.00%
URGN
PS Ratio:
9.2
URGN
PSG Ratio:
0.1
URGN
Forward Revenue Growth (12 month):
65.90%
URGN Articles
No data was found